Biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) announced on Thursday that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for ivonescimab in combination with chemotherapy for patients with EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) following tyrosine kinase inhibitor (TKI) therapy.
The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal action date of 14 November 2026.
Summit's BLA submission is based on results from the global Phase III HARMONi study, which compared ivonescimab plus platinum-doublet chemotherapy with placebo plus platinum-doublet chemotherapy in previously TKI-treated patients. Over 14,000 patients in the United States are eligible for treatment in this setting, highlighting the significant unmet medical need addressed by ivonescimab.
The FDA plans to conduct a complete review following Good Review Management Principles, including mid-cycle and wrap-up meetings, and will propose labelling subject to the review outcome.
Summit Therapeutics and GSK form collaboration to study ivonescimab combination therapy
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Merck completes acquisition of Cidara Therapeutics for USD9.2bn
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
Kelun-Biotech lung cancer drug granted Breakthrough Therapy Designation in China
INOVIO's INO-3107 Biologics License Application accepted by US FDA
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
GSK agrees US pricing framework to expand access to respiratory medicines
Century Health partnerss with Tessel Biosciences to advance early drug development in COPD